

First name / Surname: Daniela Arduini

Adress(es): [REDACTED] Roma, Italia

Mobile: +39 [REDACTED]

Email: [REDACTED]

Nationality: Italian / Czech

Date of birth: 20.06.1990



- Registered in the Register of Medical Doctors in Rome (06/04/2020), registration num: 65902
- Registered in the Regional Register of Biologists, section A (03/23/2017), registration num: AA_077821

EDUCATION & QUALIFICATION

2009 High school diploma – Liceo Classico Gaetano De Sanctis, Rome, Italy

2012 Bachelor's degree in health Biotechnology (3 years) – Catholic University in Rome *with a score of 110/110 cum laude*

2014 Master's degree in medical Biotechnology (2 years) – Catholic University in Rome *with a score of 110/110 cum laude* "Study the role of magnesium transporters in normal and pathological proliferation" - **Prof. F. Wolf**

2019, Master degree in Medicine and Surgery (6 years)– Sapienza University in Rome (Sant'Andrea hospital) *with a score of 110/110 cum laude* **January 2021 – until January 2026**

Doctor undergoing specialised medical training in **Medical Oncology** at Catholic University of Rome, Gemelli Hospital, Rome Italy (Prof. G. Tortora)

June 2026 – until now

Self-employed medical oncologist at Comprehensive Cancer Center, Fondazione Policlinico Universitario "A. Gemelli", Rome, Italy

Certificate of Achievement – Cancer Genomics and Precision Oncology course – **Harvard Medical School**

SCIENTIFIC WORK EXPERIENCE

2010 – 2014, Practice in laboratories at Catholic University of Rome

2015 – 2019, Practice at Sant'Andrea Hospital, Rome, Italy

2016, Visiting scientist and Italian counselor - Biotech Longrich Industry - Jiangsu, China - Manila, Philippines (August 2016)

2017, Editor and teacher of the preparatory course for health professions's admission test (Istituto Bonificio VIII - Agnani, Frosinone, Italy 2017)

2018, Erasmus student at Charles University, Faculty of Medicine and Surgery – Prague, Czech Republic (April – June 2018)

2019, Scientific collaboration at IRCCS NEUROMED – Mediterranean Neurological Institute, Pozzilli, Molise, Italy - Prof. Ferdinando Nicoletti. "Role of metabotropic glutamate receptors as a pharmacological target in the treatment of glioblastoma multiforme"

SUB-INVESTIGATOR

Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy (MK-011)
A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor (TNivo2)
An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer (EV-302)
A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
Phase II study of axitinib intensification plus nivolumab compared to nivolumab alone after induction with nivolumab plus ipilimumab in mRCC patients without previous complete response (AxIn study).
A multi-center phase 2 study of neoadjuvant immunotherapy in combination with the the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer (Catalym)
A Randomized open-label phase 3 study of XL092 + Nivolumab vs Sunitinib in subjects with Advanced or Metastatic non-clear cell renal cell carcinoma (STELLAR)
PH-L19TNFDOX2-03/16 (FIBROSARC) A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma
A randomized study to investigate the efficacy and safety of the tumor-targeting human antibody-cytokine fusion protein L19TNF in previously treated patients with advanced stage or metastatic soft-tissue sarcoma"
A Phase 2, randomized, double-blind, clinical study of V940 (mRNA-4157) plus pembrolizumab (MK-3475) versus placebo plus pembrolizumab in the adjuvant treatment of participants with renal cell carcinoma
A phase 2, randomized, double-blind, placebo-and active comparator cotrolled clinical study of adjuvant V940 (mRNA-4157) plus pembrolizumab versus adjuvant placebo plus pembrolizumab in participants with high-risk muscle-invasive urothelial carcinoma post-radical resection

AWARDS

2010 and 2012: Winner of a Research grants at the Department of General Pathology – Catholic University of Rome. Aim of the research: “Study the role of magnesium transporters in normal and pathological proliferation”

2014: Winner of the “**Premio Gemelli**” as the best graduate of the Faculty of Medicine and Surgery (2014), Catholic University in Rome (Alumni Cattolica)

2019: Admitted to the “**Percorso di eccellenza**” of the Faculty of Medicine and Surgery - University La Sapienza of Rome, Hospital Sant’Andrea

2025: Conquer Cancer Merit Award – 2025 ASCO Genitourinary Cancers Symposium Program Committee, USA

SCIENTIFIC CONGRESSES

- Poster session – 1° Multidisciplinary Congress of Italian Researchers at the Italian Cultural institute, Italian Embassy in Prague, 18-20 June 2019 – Prof. Luca Vannucci
- **Local Organizing Committee** - XIV International Magnesium Symposium, Rome Villa Malta, 23-24 June 2016 (Director: Prof. F. Wolf)
- **Second place** for the best presentation in the Poster session, at the Workshop entitled "Magnesium in Translational Medicine"; Smolenice Castle / Slovak Republic (11-15 May 2014)
- **Third place** for the best scientific exhibition in the "Basic Science" session, at Semmelweis International Students 'Conference 2014; Budapest / Hungary (2-4 April 2014)
- Xylella fastidiosa associated to the Olive Quick Decline Syndrome (OQDS) in Southern Italy: Natural Outbreak or Agroterrorism? University of Tor Vergata, International Master Courses in protection against CBRN
- Cardiovascular effects of abiraterone and PARP-inhibitor combinations in metastatic castration resistant prostate cancer: a meta-analysis, Poster section AIOM 2022
- Poster session for one abstract selected for **Merit Award** at 2025 ASCO Genitourinary Cancer Symposium at San Francisco, USA (13-15 February 2025)
- Poster session for one abstract selected for **IKCS** International Kidney Cancer Symposium, Amsterdam (1-3 May 2025)
- Oral presentation at congress “The role of Liquid Biopsy in Cancer”, Pompei, Italy Chair: prof. Malapelle

PUBLICATIONS

1. Magnesium Modulates Doxorubicin Activity through Drug Lysosomal Sequestration and Trafficking. Trapani V, Luongo F, Arduini D, Wolf FI. ChemRes Toxicol. 2016 Mar 21;29(3):317-22.
2. EGF stimulates Mg(2+) influx in mammary epithelial cells Trapani V, Arduini D, Luongo F, Wolf FI. Biochem Biophys Res Commun. 2014 Nov 28;454(4):572-5.
3. From magnesium to magnesium transporters in cancer: TRPM7, a novel signature in tumour development. Trapani V, Arduini D, Cittadini A, Wolf FI. Magnes Res. 2013 Oct-Dec;26(4):149-55. Review.
4. Dietary Magnesium Alleviates Experimental Murine Colitis Through Upregulation of the Transient Receptor Potential Melastatin 6 Channel. Trapani V, Petito V, Di Agostini A, Arduini D, Hamersma W, Pietropaolo G, Luongo F, Arena V, Stigliano E, Lopetuso LR, Gasbarrini A, Wolf FI, Scaldaferri F. Inflamm Bowel Dis. 2018 Sep 15;24(10):2198-2210.
5. The Threat of Plant Toxins and Bioterrorism: A Review. Ludovici GM, Arduini D, Gaudio P, Chierici A, Manenti G, Malizia A. Defence S&T technical Bulletin, 2022 Vol. 15, Num 1.
6. Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers. Iacovelli R, Arduini D, Ciccarese C, Pierconti F, Strusi A, Piro G, Carbone C, Foschi N, Daniele G, Tortora G. Crit Rev Oncol Hematol. 2022 Aug;176:103750. doi: 10.1016/j.critrevonc.2022.103750. Epub 2022 Jun 18. PMID: 35728738.
7. Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario. Ciccarese C, Strusi A, Arduini D, Russo P, Palermo G, Foschi N, Racioppi M, Tortora G, Iacovelli R. Cancer Treat Rev. 2023 Apr;115:102528. doi: 10.1016/j.ctrv.2023.102528. Epub 2023 Feb 24. PMID: 36905896.
8. 2024 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma. Beccia V, Arduini D, Iacovelli R, Scala A, Occhipinti D, Ligato C, Roca L, Russo P, Foschi N, Tortora G, Ciccarese C. Expert Rev Anticancer Ther. 2024 Aug;24(8):657-660. doi: 10.1080/14737140.2024.2370382. Epub 2024 Jun 27. PMID: 38912860.
9. The Clinical Role of Hypoxia Inducible Factor (HIF) Inhibition in Renal Cancer: A Focus on Belzutifan. Arduini D, Ciccarese C, Strusi A, Beccia V, Pedone RR, Scala A, Sardaro V, Tortora G, Iacovelli R. Curr Cancer Drug Targets. 2025 Jan 6. doi: 10.2174/0115680096323507241101064127. Epub ahead of print. PMID: 39779574.
10. A phase II study of nivolumab plus metformin in pre-treated metastatic renal cell carcinoma patients. NivoMet TWINS-GU002 Study" in press

PERSONAL SKILLS
AND COMPETENCES

- ECDL - European Computer Driving Licence
- BLSD - Basic Life Support and Defibrillation, Healthcare Provider – International Licence

LANGUAGES

Mother tongue

- Italian
- Czech

Other languages

English

UNDERSTANDING

SPEAKING

WRITING

Excellent

Excellent

Excellent

C1 - Morehampton Language Institute Dublin – Irland

No conflict of interest

21.10.2025

Daniela Arduini

